A series of nanoscaled Pt(0)‐phosphorus ylide complexes based on [60]fullerene: Synthesis, characterization, and in vitro biological assessments

Abstract

AbstractHerein, A type of Pt(0) complexes based on fullerene C60 including phosphorus ylides as monodentate ligands, [(η2‐C60)Pt(Y1–4)2] (Y1 = PPh3CHC(O)C6H4‐p‐NO2, Y2 = PPh3CHC(O)C6H4‐p‐CH3, Y3 = (p‐tolyl)3P‐CHC(O)C6H4‐p‐NO2, Y4 = (p‐tolyl)3P‐CHC(O)C6H4‐p‐CH3), were synthesized via adding of related monodentate phosphorus ylide to toluene solution of C60 and Pt (dba)2 (dba = dibenzylideneacetone). The structures were identified using IR, NMR (1H, 13C, and 31P), UV–visible, ESI‐MS, and EDX spectroscopies, thermal curve TGA, and electron microscopic images (scanning electron microscopy, SEM, and transmission electron microscopy, TEM). The molecular structure of complexes clearly shows that two ylidic ligands in a cis configuration and two hexagons of C60 in the junction[6,6] coordinate to Pt(0) metal center. These complexes were treated as biological agents in antibacterial, antioxidant, and anticancer assessments. Three Gram‐negative (Escherichia coli, Salmonella typhimurium, and Shigella dysenteriae) and three Gram‐positive bacteria (Bacillus subtilis, Bacillus cereus, and Staphylococcus aureus) were used for antibacterial investigation. The activities of complexes against cancer cells were also tested using AGS (gastric carcinoma), A549 (non‐small lung carcinoma), and MCF‐7 (breast carcinoma) cell lines. All biological studies on synthesized nanocomplexes showed promising effects in comparison with standards.